HIMS News and Press, Hims & Hers Health Inc. Class A From 06/24/24

2024-06-24 09:37:14 ET Fool.com contributor Parkev Tatevosian evaluates Hims & Hers Health (NYSE: HIMS) stock for long-term investors. *Stock prices used were the afternoon prices of June 20, 2024. The video was published on June 22, 2024. Continue reading ...

2024-06-24 08:30:00 ET Summary After a parabolic run in recent months, HIMS stock took a double-digit plunge last week in an apparent loss of technical momentum. While its technical correction may lead to a deeper pullback in the near term, Hims & Hers' robust business momentu...

2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...

2024-06-20 13:27:30 ET More on iShares Russell 3000 ETF: IWV: Future Performance Will Likely Remain Slightly Inferior To The S&P 500 Index Layoffs mentions by Russell 3000 companies are elevated but trending lower vs history The big risk of AI spending is margin ...

2024-06-18 03:05:48 ET Summary As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. ...

2024-06-13 16:00:00 ET Summary HIMS has proven that a telehealth platform can remain relevant in a rapidly changing landscape, by opting to cater to the retail healthcare market through customized prescription/ over-the-counter medications. This is attributed to its in-house pharm...

Hims & Hers Health, Inc. (NYSE: HIMS) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.97% on the day to $23.45. Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The com...

2024-06-10 15:47:28 ET Summary Hims & Hers has rallied substantially this year as it started to show its profitability chops. Despite guiding for a >$1 billion annualized revenue scale in 2024, the company is still expected to grow revenue north of 40%+ and have 80%+ pro fo...

2024-06-10 12:06:11 ET Summary Hims & Hers stock has easily outperformed the market over the past year, surging almost 130%. Hims & Hers' personalized care platform is a critical growth driver poised to expand further. Hims & Hers is targeting the weight loss drugs...

2024-06-10 04:41:47 ET Summary Hims & Hers boasts booming revenue, but faces a commoditized business model with intense competition. High marketing expenses raise concerns about customer retention and unit economics. Decelerating revenue growth, potential margin contractio...